Observational studyJournal of thrombosis and haemostasis : JTH2021
SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study.
Observational study in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Thrombotic risk in children with COVID-19 infection: A systematic review of the literature.Thrombosis research · 2021Pooled it
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Policy Adherence to Antithrombotic Therapy for Prophylactic Anticoagulation in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19.Journal of pediatrics. Clinical practice · 2025Article
- Review
- SARS-CoV-2 Variants and Their Impact on Pediatric COVID-19: Clinical Manifestations and Hematological Profiles.Diseases (Basel, Switzerland) · 2025Article
- Article
- The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement.Clinical and experimental medicine · 2024Article
- COVID-19 and Thromboembolic Events in the Pandemic and Pre-Pandemic Era: A Pediatric Cohort.Viruses · 2023Article
- Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review.Paediatric drugs · 2023Review
- Evaluation of antithrombotic prophylaxis and thrombotic events in children with COVID-19 or MIS-C: A tertiary pediatric center experience.Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 2023Article
- Purpura Fulminans After Varicella Infection and Pulmonary Embolism After COVID-19 Infection in Familial Mediterranean Fever: Coincidence or Not?Turkish archives of pediatrics · 2023Article
- COVID-19-associated coagulopathy in children: A multicenter observational cohort study.Pediatric blood & cancer · 2023Observational
- Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.Research and practice in thrombosis and haemostasis · 2022Article
- Thrombosis and hemorrhage experienced by hospitalized children with SARS-CoV-2 infection or MIS-C: Results of the PICNIC registry.Pediatric blood & cancer · 2022Article
- Imaging findings in acute pediatric coronavirus disease 2019 (COVID-19) pneumonia and multisystem inflammatory syndrome in children (MIS-C).Pediatric radiology · 2022Review
- Thromboprophylaxis for children hospitalized with COVID-19 and MIS-C.Research and practice in thrombosis and haemostasis · 2022Article
- Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model.EJHaem · 2022Article
- Thromboembolic complications in children with COVID-19 and MIS-C: A narrative review.Frontiers in pediatrics · 2022Review
- Therapeutic Strategies for COVID-19 Lung Disease in Children.Frontiers in pediatrics · 2022Review
- Review of COVID-19, part 1: Abdominal manifestations in adults and multisystem inflammatory syndrome in children.Clinical imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple investigators have described an increased incidence of thromboembolic events in SARS-CoV-2-infected individuals. Data concerning hemostatic complications in children hospitalized for COVID-19/multisystem inflammatory syndrome in children (MIS-C) are scant.
objectivesTo share our experience in managing SARS-CoV-2-associated pro-coagulant state in hospitalized children.
methodsD-dimer values were recorded at diagnosis in children hospitalized for SARS-CoV-2-related manifestations. In moderately to critically ill patients and MIS-C cases, coagulation and inflammatory markers were checked at multiple time points and median results were compared. Pro-thrombotic risk factors were appraised for each child and thromboprophylaxis was started in selected cases.
resultsThirty-five patients were prospectively enrolled. D-dimer values did not discriminate COVID-19 of differing severity, whereas were markedly different between the COVID-19 and the MIS-C cohorts. In both cohorts, D-dimer and C-reactive protein levels increased upon clinical worsening but were not accompanied by decreased fibrinogen or platelet values, with all parameters returning to normal upon disease resolution. Six patients had multiple thrombotic risk factors and were started on pharmacological thromboprophylaxis. No deaths or thrombotic or bleeding complications occurred.
conclusionsCOVID-19 pediatric patients show mildly altered coagulation and inflammatory parameters; on the other hand, MIS-C cases showed laboratory signs of an inflammatory driven pro-coagulant status. Universal anticoagulant prophylaxis in hospitalized children with SARS-CoV-2-related manifestations is not warranted, but may be offered to patients with other pro-thrombotic risk factors in the context of a multi-modal therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.